|
1
|
Brahmer JR, Govindan R, Anders RA, Antonia
SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon
EB, et al: The Society for Immunotherapy of Cancer consensus
statement on immunotherapy for the treatment of non-small cell lung
cancer (NSCLC). J Immunother Cancer. 6:752018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lei Z, Shi H, Li W, Yu D, Shen F, Yu X, Lu
D, Sun C and Liao K: MiR-185 inhibits non-small cell lung cancer
cell proliferation and invasion through targeting of SOX9 and
regulation of Wnt signaling. Mol Med Rep. 17:1742–1752.
2018.PubMed/NCBI
|
|
3
|
Tanaka F and Yoneda K: Adjuvant therapy
following surgery in non-small cell lung cancer (NSCLC). Surg
Today. 46:25–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sotgia F and Lisanti MP: Mitochondrial
markers predict survival and progression in non-small cell lung
cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget.
8:68095–68107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin D, Lu X, Su J, He X, De W, Yang J, Li
W, Han L and Zhang E: Long noncoding RNA AFAP1-AS1 predicts a poor
prognosis and regulates non-small cell lung cancer cell
proliferation by epigenetically repressing p21 expression. Mol
Cancer. 17:922018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo X, Wei Y, Wang Z, Liu W, Yang Y, Yu X
and He J: LncRNA LINC00163 upregulation suppresses lung cancer
development though transcriptionally increasing TCF21 expression.
Am J Cancer Res. 8:2494–2506. 2018.PubMed/NCBI
|
|
7
|
Pei W, Dong C, Hongbing M and Yong L: Long
non-coding RNA MEG3 regulates proliferation and apoptosis in
non-small cell lung cancer via the miR-205-5p/LRP1 pathway. Rsc
Adv. 7:49710–49719. 2017. View Article : Google Scholar
|
|
8
|
Cai Y, Sun Z, Jia H, Luo H, Ye X, Wu Q,
Xiong Y, Zhang W and Wan J: Rpph1upregulates CDC42 expression and
promotes hippocampal neuron dendritic spine formation by competing
with miR-330-5p. Front Mol Neurosci. 10:272017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang P..Sun Y..Peng R..et al: Long
non-coding RNA Rpph1 promotes inflammation and proliferation of
mesangial cells in diabetic nephropathy via an interaction with
Gal-3. Cell Death Dis. 10:5262019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang ZX, Liu HS, Wang FW, Xiong L, Zhou
C, Hu T, He XW, Wu XJ, Xie D, Wu XR and Lan P: LncRNA RPPH1
promotes colorectal cancer metastasis by interacting with TUBB3 and
by promoting exosomes-mediated macrophage M2 polarization. Cell
Death Dis. 10:8292019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lei B, He A, Chen Y, Cao X, Zhang P, Liu
J, Ma X, Qian L and Zhang W: Long non-coding RNA RPPH1 promotes the
proliferation, invasion and migration of human acute myeloid
leukemia cells through down-regulating miR-330-5p expression. EXCLI
J. 18:824–837. 2019.PubMed/NCBI
|
|
12
|
Jiang H, Liang M, Jiang Y, Zhang T, Mo K,
Su S, Wang A, Zhu Y, Huang G and Zhou R: The lncRNA TDRG1 promotes
cell proliferation, migration and invasion by targeting miR-326 to
regulate MAPK1 expression in cervical cancer. Cancer Cell Int.
19:1522019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang R, Chen X, Xu T, Xia R, Han L, Chen
W, De W and Shu Y: MiR-326 regulates cell proliferation and
migration in lung cancer by targeting phox2a and is regulated by
HOTAIR. Am J Cancer Res. 6:173–186. 2016.PubMed/NCBI
|
|
14
|
Ghaemi Z, Soltani BM and Mowla SJ:
MicroRNA-326 functions as a tumor suppressor in breast cancer by
targeting ErbB/PI3K signaling pathway. Front Oncol. 9:6532019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu W, Zhang B, Xu N, Wang MJ and Liu Q:
MiR-326 regulates EMT and metastasis of endometrial cancer through
targeting TWIST1. Eur Rev Med Pharmacol Sci. 21:3787–3793.
2017.PubMed/NCBI
|
|
16
|
Wang B, Sun L, Li J and Jiang R: MiR-577
suppresses cell proliferation and epithelial-mesenchymal transition
by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small
cell lung cancer. Mol Med Rep. 18:2753–2761. 2018.PubMed/NCBI
|
|
17
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hai J, Zhu CQ, Wang T, Organ SL, Shepherd
FA and Tsao MS: TRIM14 is a putative tumor suppressor and regulator
of innate immune response in non-small cell lung cancer. Sci Rep.
7:396922017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stinchcombe TE and Socinski MA: Current
treatments for advanced stage non-small cell lung cancer. Proc Am
Thorac Soc. 6:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Ma L, Xu F, Zhai W, Dong S, Yin L,
Liu J and Yu Z: Role of long non-coding RNA in drug resistance in
non-small cell lung cancer. Thorac Cancer. 9:761–768. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmitt AM and Chang HY: Long Noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Noh JH, Kim KM, McClusky WG, Abdelmohsen K
and Gorospe M: Cytoplasmic functions of long noncoding RNAs. Wiley
Interdiscip Rev RNA. 9:e14712018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang C, Li X, Zhao H and Liu H: Long
non-coding RNAs: Potential new biomarkers for predicting tumor
invasion and metastasis. Mol Cancer. 15:622016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi
Y and Guo J: Long noncoding RNA associated-competing endogenous
RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leonard L, Dachet F, Cai J, Bagla S, Balan
K, Jia H and Loeb JA: Activity-dependent human brain
coding/noncoding gene regulatory networks. Genetics. 192:1133–1148.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun C, Huang C, Li S, Yang C, Xi Y, Wang
L, Zhang F, Fu Y and Li D: Hsa-miR-326 targets CCND1 and inhibits
non-small cell lung cancer development. Oncotarget. 7:8341–8359.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun Y, Zheng S, Torossian A, Speirs CK,
Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of
insulin-like growth factor-1 signaling pathway in
cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol
Phys. 82:e563–e572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Li S, Chen Z, Wang J, Chen Y, Xu Z,
Jin M and Yu W: MiR-326 reverses chemoresistance in human lung
adenocarcinoma cells by targeting specificity protein 1. Tumour
Biol. 37:13287–13294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Katoh M: Differential regulation of WNT2
and WNT2B expression in human cancer. Int J Mol Med. 8:657–660.
2001.PubMed/NCBI
|
|
33
|
Li SJ, Yang XN and Qian HY: Antitumor
effects of WNT2B silencing in GLUT1 overexpressing cisplatin
resistant head and neck squamous cell carcinoma. Am J Cancer Res.
5:300–308. 2014.PubMed/NCBI
|
|
34
|
Kobayashi M, Huang CL, Sonobe M, Kikuchi
R, Ishikawa M, Kitamura J, Miyahara R, Menju T, Iwakiri S, Itoi K,
et al: Intratumoral Wnt2B expression affects tumor proliferation
and survival in malignant pleural mesothelioma patients. Exp Ther
Med. 3:952–958. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J,
Lu Y, Wang C, Ma D and Huang X: Silencing Wnt2B by siRNA
interference inhibits metastasis and enhances chemotherapy
sensitivity in ovarian cancer. Int J Gynecol Cancer. 22:755–761.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang H, Li F, He C, Wang X, Li Q and Gao
H: Expression of Gli1 and Wnt2B correlates with progression and
clinical outcome of pancreatic cancer. Int J Clin Exp Pathol.
7:4531–4538. 2014.PubMed/NCBI
|
|
37
|
Liu C, Li G, Yang N, Su Z, Zhang S, Deng
T, Ren S, Lu S, Tian Y, Liu Y and Qiu Y: MiR-324-3p suppresses
migration and invasion by targeting WNT2B in nasopharyngeal
carcinoma. Cancer Cell Int. 17:22017. View Article : Google Scholar : PubMed/NCBI
|
